Evidence map›Paper›PMID 42470530›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

Advances in applications of siRNA in cancer therapy: challenges and opportunities.

Mohamad Mehrparvar, Shima Shabani, Farshid Oruji, Saba Hajazimian, Hadi Nasiri, Soolmaz Khansalar, Javad Behroozi, Alireza Isazadeh, Morteza Akbari

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohamad MehrparvarImmunology Research Center, Tabriz University of Medical Sciences, Daneshghah Ave, Tabriz, Iran.
Shima ShabaniPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA.
Farshid OrujiDepartment of Genetics, College of Medicine, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE, USA.
Saba HajazimianImmunology Research Center, Tabriz University of Medical Sciences, Daneshghah Ave, Tabriz, Iran.
Hadi NasiriImmunology Research Center, Tabriz University of Medical Sciences, Daneshghah Ave, Tabriz, Iran.
Soolmaz KhansalarShiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID http://orcid.org/0009-0003-5888-1883
Javad BehrooziDepartment of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Alireza IsazadehImmunology Research Center, Tabriz University of Medical Sciences, Daneshghah Ave, Tabriz, Iran.
Morteza AkbariImmunology Research Center, Tabriz University of Medical Sciences, Daneshghah Ave, Tabriz, Iran. akbarimo@tbzmed.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review comprehensively examines recent advances in the application of small interfering RNA (siRNA) in cancer therapy. The introductory section highlights the complex mechanisms of siRNA and its critical role in gene regulation and silencing, which are essential for inhibiting cancer progression. A detailed discussion explores combination therapy approaches, focusing on how siRNA can be integrated with conventional and emerging therapeutic modalities to achieve synergistic effects. Particular emphasis is placed on the potential of these combination strategies to enhance therapeutic efficacy and improve treatment outcomes. The review also summarizes key clinical trials that provide valuable insights into the progress of siRNA-based therapeutics. Despite these advances, the clinical application of siRNA in cancer therapy continues to face significant challenges, particularly with respect to delivery systems and off-target effects. Through a critical evaluation of these opportunities and limitations, this review highlights the potential of siRNA as a promising therapeutic tool in oncology while emphasizing the need for further research to optimize its clinical translation.

Indexed as

Cancer therapyClinical applicationsPrecision medicineShort interfering RNA

Identifiers

PMID42470530

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.